Summary: AlphaThera continues to scale commercialization of its site-specific antibody conjugation products and has encountered welcoming signs of consumer interest across the US and the world, with sales in several countries and continued customer inquiries. However, increasing expenses associated with scaling and commercialization have led us to explore additional sources of funds. The TABA funds offered by the NIH/SBIR to support Phase I/Phase II grants are an ideal source of funding to enable AlphaThera to continue on its fast-track towards scaled commercialization success. TABA funding will be allocated toward three major categories in support of our commercialization: Multi-channel marketing; Strategic partner development and IP protection.